LAE-111

N/A

Report date: 2023/11/06 14:34:33

Base Information

Drug NameLAE-111

Drug Alias NameLAE-111

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionNatural killer cells modulatorsLeukocyte immunoglobulin-like receptor B1 inhibitorsanti-Leukocyte immunoglobulin-like receptor subfamily B member 2

TargetsLeukocyte immunoglobulin-like receptor B1Leukocyte immunoglobulin-like receptor subfamily B member 2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLaekna Therapeutics Shanghai Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesLaekna Therapeutics Shanghai Co Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A